The week in health tech, explained in plain English.Get the free newsletter →
October 31, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Payers

AI Job Fears Top of Mind for Health Plan Employees

"Is AI going to take my job?" is a question health plan leaders are hearing more often from their own staff, according to Becker's Hospital Review. The anxiety comes against a backdrop of payers across the country cutting jobs, and it intensified after Centene confirmed it is offering buyouts to most employees as its Affordable Care Act business contracts.

That combination of layoffs and rapid AI adoption has pushed employee morale and retention to the top of leaders' agendas. Becker's spoke with executives including those at Sidecar Health about how to keep staff engaged when the technology reshaping their work also feels like a threat to it.

The practical message leaders are pushing is that AI should handle repetitive tasks and augment workers rather than replace them. But with concrete job cuts already happening across the sector, reassurance alone may not settle the question for employees watching their colleagues take buyouts.

More in Payers

Payers

CMS Releases 2027 Medicare Advantage Star Ratings

CMS released its 2027 Medicare Advantage star ratings on Oct. 8, shaping quality bonus payments and how insurers compete for members.

Why it matters: Star ratings control billions in quality bonus payments that determine how generous Medicare Advantage plans can be.

Payers

Walmart to Make Some GLP-1s Free for Diabetic Workers in 2027

Walmart will make more than 250 medications, including some GLP-1s for Type 2 diabetes, free to employees starting in 2027.

Why it matters: How a major self-insured employer like Walmart structures GLP-1 coverage signals where corporate drug benefits are heading amid soaring demand.

Payers

Patients Are Taking Insurance Denials Straight to the C-Suite

Some patients are overturning insurance denials by emailing insurer CEOs directly, a workaround that exposes deeper flaws in the standard appeals process.

Why it matters: When patients must reach the CEO to get covered care approved, it signals the normal denial and appeals system is failing the people it should serve.